Dry Powder Inhaler Market

Global Dry Powder Inhaler Market Size (2024 to 2029)

The size of the global dry powder inhaler market is expected to be valued at USD 20.3 Bn in 2024 and USD 26.16 Billion by 2029, growing CAGR of 5.2% from 2024 to 2029.

A dry powder inhaler (DPI) is a device type that delivers medication to the lungs in the form of dry powder. These are majorly used to treat respiratory diseases such as asthma, bronchitis, emphysema, and Chronic Obstructive Pulmonary Disease (COPD). The dry powder inhalers are used in treating diabetes mellitus in the form of inhalable insulin. These devices are used as an alternative to aerosol-based inhalers. The dose delivered by these devices is typically less than a few tens of milligrams in a single breath, as the larger doses lead to the provocation of cough. Most of the DPIs depend on the force of patient inhalation to entrain the powder from the device and then break the powder into smaller particles that are enough to reach the lungs. 

Global Dry Powder Inhaler Market Drivers:

The growing prevalence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease and chronic bronchitis is primarily contributing to the growth of the global dry powder inhaler market. According to the World Health Organization (WHO), nearly 300 million people worldwide have asthma and around 240 million people are suffering from Chronic Obstructive Pulmonary Disease (COPD). Over half of these patients prefer to take dry powder inhaler medication for treatment of these conditions. These factors are increasing the demand for inhalation devices that are practical and convenient for patients. All these factors enhance global market growth. The growing number of older adults worldwide is increasing the prevalence of respiratory illness, and the demand for dry powder inhalers increases in the forecast period. The rising demand for personalized medicine among the people is due to specific requirements of the patient. Customized medicine formulations and delivery systems are supporting the global market expansion. The features of the dry powder inhalers, such as ease of use, ability to carry the inhalers, and dosage levels, are all appealing, which boosts global market expansion. 

There are growing government initiatives for promoting people's respiratory health, where the government authorities are running campaigns and various programs to educate people regarding respiratory diseases and treatment options. The increasingly favorable commitments by the government by providing approvals, regulatory licenses, and policies to compensate the medication to the people all these factors are enhancing the global adoption of DPIs, which is impacting the global market growth.

The growing technological advancements in the pharmaceutical industry and rising investments in the R&D sector by the major market players and government organizations are expected to provide market growth opportunities during the forecast period. Most of the market players are collaborating with pharmaceutical companies and technology providers, which is leading to advancements in inhalation techniques, composition, and design. These increasing partnerships are expected to improve the capabilities of the inhalers by enhancing the global market growth during the forecast period. The rising drug delivery technologies are constantly evolving, making dry powder inhalers more effective and user-friendly and augmenting global market growth in the upcoming years.

Global Dry Powder Inhaler Market Restraints:

The primary factor restraining the global dry powder inhalers is the storage conditions. As the medication is available in powder form, it does not have a longer shelf-life and stability for long-period usage. The dry powder should be stored in dry conditions to avoid humidity, which is expected to limit the global market expansion. Most inhalers consist of lactose to increase the flow-ability and deliver the active pharmaceutical ingredient. The presence of lactose is in very tiny amounts, but it causes complications for people allergic to milk and milk products. This is expected to hamper the global market growth during the forecast period. Another factor hindering the global market expansion is the high costs of dry powder inhalers and the presence of alternatives such as nebulizers and pressurized metered-dose inhalers, which are expected to restrain global market revenue.

The dosage of the medication by dry powder inhaler depends on the forceful pressure applied by the patient during inhalation, which varies according to the person. It is challenging for manufacturers to develop devices that deliver uniform dosages to patients. For patients requiring a high dosage volume, delivering the correct dosage could be more efficient. These factors are expected to hamper market expansion. The escalating regulatory issues during the approval and production are estimated to be challenging as various regulatory authorities need to give approval, which is a complex and time-consuming process that may delay production and impact market revenue. 

Impact of COVID-19 on the dry powder inhaler market:

The Pandemic had a mixed impact on the global dry powder inhaler market due to stringent lockdown regulations; manufacturing and production are delayed, impacting the market revenue. The supply chain disruption due to Pandemic regulations also impacted the market growth. However, COVID-19 patients had symptoms of shortness of breath, which increased the demand for inhalers during the Pandemic. Post-pandemic, the global dry powder inhalers market is estimated to increase sales, advancements, and efficacy during the forecast period.

REPORT COVERAGE:

This research report on the global dry powder inhaler market is segmented and sub-segmented into following categories.

Global Dry Powder Inhaler Market - By Product:

• Single Dose Dry Powder Inhalers 
• Multi-Dose Dry Powder Inhalers 

The multi-dose dry powder inhaler segment dominated the global market revenue with the largest share of 58.2% in 2023 due to its advantages to patients. These devices deliver multiple dosage units for a specified indication of the patient for quick action on the lungs, which improves patient outcomes and is convenient to use, driving the segment growth. Most patients prefer multi-dose devices as they are affordable and incorporate various dosage forms, eliminating carrying multiple inhalers and boosting the global market revenue. Multi-dose dry powder inhalers are highly preferred for patients with COPD and asthma due to their effectiveness as a lung medication. 

The single-dose dry powder inhalers segment is anticipated to grow significantly during the forecast period due to growing inhalation therapies in emergencies. These devices administer the premeasured amount of medicine in a single-use inhaler. In most emergency or rescue conditions, single-dose devices are used, which is expected to expand the global market. 

Global Dry Powder Inhaler Market - By Indication:

• Asthma 
• Chronic Obstructive Pulmonary Disease (COPD)
• Chronic Bronchitis 
• Others 

The Asthma segment is expected to hold a significant market share of 43.6% in 2023 of the global market revenue. Asthma is one of the most common respiratory diseases among the global population due to the increasing prevalence of infectious diseases and air pollution in emerging economies, which is boosting segment growth. Asthma is the leading chronic disease in children; currently, around 4.5 million children under the age of 18 have asthma. 

The COPD segment is projected to have a dominant share during the forecast period. The growing number of aging people smoking is inducing COPD conditions where the airways are blocked, making it hard to breathe. Dry powder inhalation is the first preference for COPD as it delivers medicine directly to the lungs and provides rapid symptom relief. The increasing incidence of respiratory diseases worldwide is estimated to drive the segment growth. 

Global Dry Powder Inhaler Market - By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies 
• Online Pharmacies 
• Drug Stores

The hospital pharmacies acquired a significant global market revenue share, with the most outstanding share in 2023. The growing number of hospital pharmacies across regions like India, Brazil, and China and rising prescriptions of dry powder inhalers from health professionals are boosting the global market growth. Offline sales held the world's largest market share of 93% compared to online sales in the dry powder inhalers. 

The online pharmacies segment is expected to witness significant growth with a prominent CAGR due to the increasing adoption of online retailing among people. The Pandemic has influenced people to adopt digital platforms and door delivery, propelling global market revenue. 

Global Dry Powder Inhaler Market - By Region:

• North America
• Europe
• Asia Pacific 
• Latin America
• Middle East and Africa

The North American region dominated the global dry powder inhaler market with a significant share in 2023 due to the rising prevalence of respiratory illness, with advanced technology in the region's healthcare system. The North American region is projected to have a dominant share during the forecast period due to rising demand for portable and user-friendly devices. The growing aging population with the incidence of respiratory problems, including asthma and COPD, fuels the global market revenue in the region. The rising trend of personalized medication in countries like the U.S. and Canada propels the adoption of dry powder inhalers. Presence of major market players in the region is influencing the regional market growth.

The Asia Pacific region is projected to have a significant growth rate during the forecast period due to increasing investments by the market players in R&D. The growing government initiatives to educate the people regarding respiratory illness and bring awareness about the treatment methods and their benefits are expected to augment the global market share. Since asthma and COPD are becoming prevalent in the region, the demand for dry powder inhalers is increasing, enhancing the market value. 

The European region is expected to have moderate growth during the forecast period due to the presence of advanced healthcare infrastructure in countries like Germany, the U.K., and France, which boosts the global market revenue in the forecast period. Europe held the significant market players of pharmaceuticals, R&Ds and the healthcare system which enhances the global market growth.

Key Market Players:

AstraZeneca plc, Mylan N.V, Cipla Inc., Hovione, DPI Co., Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, OPKO Health, Inc. are some of the key market players in the dry powder in the dry powder inhaler market.

Recent Market Developments:

• In September 2022, Beximco Pharmaceuticals launched ONRIVA TRIO BEXICAP, a dry Inhaler Capsule. The ONRIVA TRIO BEXICAP is indicated as maintenance therapy in severe persistent asthma. 
• In February 2022, AstraZeneca and Honeywell announced their partnership to develop next-generation respiratory inhalers using propellent HFO-1234ze, which has 99.9% less global warming potential than fuels currently used in respiratory medicines. 
• In August 2021, Pharmaxis granted Aptar Pharma an exclusive option to develop and promote high-payload dry powder inhalers.